GC
PCRX icon

Globeflex Capital’s Pacira BioSciences PCRX Stock Holding History

Globeflex Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,341
Closed -$742K – 509
2020
Q3 		$742K Sell
12,341
-2,215
-15% -$129K 0.2% 183
2020
Q2 		$764K Buy
14,556
+803
+6% +$33.6K 0.19% 186
2020
Q1 		$461K Buy
+13,753
New +$571K 0.14% 248
2017
Q1 		– Sell
-14,345
Closed -$463K – 511
2016
Q4 		$463K Buy
+14,345
New +$479K 0.12% 263
2016
Q2 		– Sell
-8,250
Closed -$437K – 507
2016
Q1 		$437K Buy
+8,250
New +$483K 0.12% 244
2014
Q4 		– Sell
-7,100
Closed -$688K – 570
2014
Q3 		$688K Buy
+7,100
New +$691K 0.08% 272

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Globeflex Capital's PCRX Position: Q4 2020 in Review

Globeflex Capital sold out of Pacira BioSciences (PCRX) in Q4 2020, closing a stake of 12,341 shares — an estimated $742K sold.

Globeflex Capital first reported a position in PCRX in Q3 2014 and held it in 6 quarters. The position peaked at $764K in Q2 2020. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2020.

  • Globeflex Capital reported no remaining Pacira BioSciences position as of Q4 2020 after selling out during the quarter.
  • Globeflex Capital sold 12,341 Pacira BioSciences shares in Q4 2020, an estimated $742K.
  • Globeflex Capital first reported a position in Pacira BioSciences in Q3 2014 and held it in 6 quarters.
  • Globeflex Capital's Pacira BioSciences position peaked at $764K in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2020.

Based on Globeflex Capital's 13F filing for Q4 2020, filed 11 Feb 2021.